A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer
Cancer Research and Treatment. 2014;46(3):234-242 
359 Phase Ib and pharmacokinetic studies of Everolimus (RAD001), a novel oral mTOR-inhibitor, with paclitaxel in patients with advanced solid tumors
European Journal of Cancer Supplements. 2004;2(8):108
A phase I study of Ro 31-7453, a novel oral cell cycle inhibitor, in combination with paclitaxel: final results
European Journal of Cancer. 2002;38:S49
Preliminary results of an ongoing phase I and pharmacokinetic study of CYC202, a novel oral cyclin-dependent kinases inhibitor, in patients with advanced malignancies
European Journal of Cancer. 2002;38:S49
Phase I, pharmacokinetic (PK) and biologic study of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin in patients with advanced solid malignancies
European Journal of Cancer. 2002;38:S54
1472 POSTER A phase I study with fosfluridine tidoxil, a novel oral fluoropyrimidine, in patients with advanced solid tumors
European Journal of Cancer Supplements. 2005;3(2):426
First results of a phase I and pharmacokinetic study of SU011248, a novel oral anti-angiogenic agent, in patients with advanced solid tumours
European Journal of Cancer. 2002;38:S17
1202 ORAL A Phase I Study of the Potent AKT Inhibitor MK-2206 in Combination With Carboplatin and Paclitaxel, Docetaxel or Erlotinib in Patients With Advanced Solid Tumours
European Journal of Cancer. 2011;47:S144-S145
1454 POSTER A phase I dose-finding study of pemetrexed combined with paclitaxel in patients with advanced solid tumors
European Journal of Cancer Supplements. 2005;3(2):421
1448 ORAL Molecular pharmacodynamic (MPD) phase I study with serial tumor and skin biopsies of the oral mTOR inhibitor Everolimus (E, RAD001) at different doses and schedules in patients (pts) with advanced solid tumors
European Journal of Cancer Supplements. 2005;3(2):419